Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

Calquence is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

9 in Pediatric Blood & Cancer. Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR ...

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

A family from South London are making a desperate appeal on behalf of their 19-year-old daughter. Natassa urgently needs to ...

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

Acute lymphocytic leukaemia (ALL) is a cancer of the blood and bone marrow, specifically affecting lymphocytes. The disease progresses rapidly and creates immature blood cells, rather than mature ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...

Chronic lymphocytic leukemia (CLL) is a type of cancer affecting the bone marrow lymphocytes. It can affect B or T cells and may be slow- or fast-growing. CLL is a common type of leukemia ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...